HK
Highly rated in
54
conditions
Highly rated in
54
conditions
Check Dr. Henry G. Kaplan's experience treating your condition:
About Dr. Henry G. Kaplan

Henry Kaplan is an Oncologist in Seattle, Washington. Kaplan has been practicing medicine for over 50 years and is highly rated in 54 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration. He is licensed to treat patients in Washington. Kaplan is currently accepting new patients.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 5 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Henry G. Kaplan it is best to call his office and ask if your insurance is accepted.


Dr. Henry G. Kaplan accepts the following insurance:

  •  Ambetter
  •  PacificSource
  •  Premera
  •  Prominence Health

Call to see if your plan is accepted.
Locations
1221 Madison St, Suite 500, Seattle, WA 98104
Background & Education
Graduate Institution
University Of Rochester School Of Medicine And Dentistry, 1972
Specialties
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Valley Medical Center
Swedish Medical Center - First Hill Campus
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

Phase I Trial of Gemcitabine and Capecitabine (Xeloda) in Patients With Advanced Pancreatic Carcinoma
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
View 4 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors